CoChat

Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer

Open access
Kim, D.-W., Kim, S.-Y., Kim, H.-K., Kim, S.-W., Shin, S.W., Kim, J.S., Park, K., Lee, M.Y., Heo, D.S. · 2007 · Annals of Oncology

The DOI matches its Crossref record; 25 of the 27 references it cites were found in a registry or an index.

Abstract

Background Genexol-PM is a novel Cremophor EL (CrEL)-free polymeric micelle formulation of paclitaxel (Taxol). This multicenter phase II study was designed to evaluate the efficacy and safety of the combination of Genexol-PM and cisplatin for the treatment of advanced non-small-cell lung cancer (NSCLC).Patients and methods Patients with advanced NSCLC received Genexol-PM 230 mg/m(2) and cisplatin 60 mg/m(2) on day 1 of a 3-week cycle as first-line therapy. Intrapatient dose escalation of Genexol-PM to 300 mg/m(2) was carried out from the second cycle if the prespecified toxic effects were not observed after the first cycle.Results Sixty-nine patients were enrolled in this study. Overall response rate was 37.7%. The median time to progression was 5.8 months and the median survival period was 21.7 months. The major non-hematologic toxic effects included grade 3 peripheral sensory neuropathy (13.0%) and grade 3/4 arthralgia (7.3%). Four patients (5.8%) experienced grade 3/4 hypersensitivity reactions. The major hematological toxic effects were grade 3/4 neutropenia (29.0% and 17.4%, respectively).Conclusion Genexol-PM plus cisplatin combination chemotherapy showed significant antitumor activity. The use of CrEL-free, polymeric micelle formulation of paclitaxel allowed administration of higher doses of paclitaxel compared with the CrEL-based formulation without significant increased toxicity.

Overview

Integrity signals

Registry

Crossref · 10.1093/annonc/mdm374

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 25 references

Cited by

See all 391

Metadata

Authors
Kim, D.-W., Kim, S.-Y., Kim, H.-K., Kim, S.-W., Shin, S. W., Kim, J. S., Park, K., Lee, M. Y., & Heo, D. S.
Affiliations
  • Seoul National University (KR)
  • Asan Medical Center (KR)
  • The Catholic University of Korea St. Vincent's Hospital (KR)
  • Korea University Anam Hospital (KR)
  • Samsung Medical Center (KR)
  • Samyang Holdings (South Korea) (KR)
Corresponding author
Heo, D.S.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2007-12
Volume
18
Issue
12
Pages
2009-2014
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2155680971
Cited by
356
References
27
Citations by year
2026: 14 · 2025: 22 · 2024: 19 · 2023: 13 · 2022: 24 · 2021: 12 · 2020: 22 · 2019: 15 · 2018: 19 · 2017: 18 · 2016: 30 · 2015: 24 · 2014: 31 · 2013: 28 · 2012: 17
FWCI
8.93
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
  • Seoul National University Open Repository (Seoul National University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
paclitaxel, polymeric micelles, cisplatin, non-small cell lung cancer, combination chemotherapy, first-line therapy, dose escalation, peripheral sensory neuropathy, neutropenia, hypersensitivity, anticancer activity
MeSH terms
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Female, Humans, Lung Neoplasms, Male, Micelles, Middle Aged, Polymers, Treatment Outcome, Paclitaxel

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. https://app.cochat.ai/papers/10.1093/annonc/mdm374
The paper
Kim, D.-W., Kim, S.-Y., Kim, H.-K., Kim, S.-W., Shin, S. W., Kim, J. S., Park, K., Lee, M. Y., & Heo, D. S. (2007). Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Annals of Oncology. https://doi.org/10.1093/annonc/mdm374

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.